In this monthly update the investment team discuss the recent data readout from phase 3 studies with the different vaccine candidates against COVID-19 from Pfizer-Biontech, Moderna and AstraZeneca-Oxford University. Furthermore, the team talks about two novel important drugs for rare diseases developed by Y-mabs and Alnylam. They look into ALX Oncology which market value nearly doubled during November after promising early-stage data in gastric cancers. And finaly some words about the US Election and possible consequences for the health care sector.
